PLoS ONE (Jan 2022)

Clinical impact of statin intensity according to age in patients with acute myocardial infarction.

  • Kyusup Lee,
  • Myunhee Lee,
  • Dae-Won Kim,
  • Jinseob Kim,
  • Sungmin Lim,
  • Eun Ho Choo,
  • Chan Joon Kim,
  • Chul Soo Park,
  • Hee Yeol Kim,
  • Ki-Dong Yoo,
  • Doo Soo Jeon,
  • Kiyuk Chang,
  • Ho Joong Youn,
  • Wook-Sung Chung,
  • Min Chul Kim,
  • Myung Ho Jeong,
  • Youngkeun Ahn,
  • Jongbum Kwon,
  • Mahn-Won Park

DOI
https://doi.org/10.1371/journal.pone.0269301
Journal volume & issue
Vol. 17, no. 6
p. e0269301

Abstract

Read online

BackgroundThe available data are not sufficient to understand the clinical impact of statin intensity in elderly patients who undergo percutaneous coronary intervention (PCI) due to acute myocardial infarction (AMI).MethodsUsing the COREA-AMI registry, we sought to compare the clinical impact of high- versus low-to-moderate-intensity statin in younger (ResultsIn younger patients, high-intensity statin showed the better clinical outcomes than low-to-moderate-intensity statin (TVF: 79 [5.4%] vs. 329 [6.8%], adjusted hazard ratio [aHR] 0.76; 95% confidence interval [CI] 0.59-0.99; P = 0.038). However, in elderly patients, the incidence rates of the adverse clinical outcomes were similar between two statin-intensity groups (TVF: 38 [11.4%] vs. 131 [10.6%], aHR 1.1; 95% CI 0.76-1.59; P = 0.63).ConclusionsIn this AMI cohort underwent PCI, high-intensity statin showed the better 1-year clinical outcomes than low-to-moderate-intensity statin in younger patients. Meanwhile, the incidence rates of adverse clinical events between high- and low-to-moderate-intensity statin were not statistically different in elderly patients. Further randomized study with large elderly population is warranted.